Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Fresenius Medical Care (FMC) St. nach folgenden Kriterien zu filtern.

Mit einem Rekordgewinn und ordentlichen Wachstumsaussichten versuchte Fresenius-Chef Ulf Schneider die Anleger an der Börse zu beeindrucken. Doch die hatten höhere Erwartungen - und schauen auf ...

There are several CDK4/6 inhibitors approved with endocrine therapy for the frontline treatment of HR-positive, HER2-negative breast cancer, including Pfizer's Ibrance (palbociclib), Novartis' Kisqali ...

In the third quarter, Lilly's revenue from the breast cancer drug Verzenio increased by 32% year over year to $1.4 billion. Sales from the immunosuppressant Taltz came in at $879.6 million ...

Sales of autoimmune disease drug Taltz, breast cancer drug Verzenio, and fast-acting insulin Humalog soared by 17% or more year over year in the third quarter of 2024. Lilly's pipeline makes it ...

This type of tumor, referred in shorthand as HR+ and HER2-, accounts for roughly 70% of all breast cancer cases in the U.S. Kisqali specifically targets a protein called CDK4/6, as does Eli Lilly’s ...

Verzenio’s label expanded to include the full study population investigated in the Verzenio Phase 3 monarchE trial. Approval supported by four-year data from the monarchE trial; Verzenio added to ...

TecDax 3.355 10:53:45-0,73% 10:53:45 ...

Lilly's Verzenio has failed to show benefits in lung cancer patients with a KRAS mutation, denting the company's hopes of millions in extra revenues. Verzenio (abemaciclib) has just gained its ...

The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer. Verzenio (abemaciclib) is now licensed to treat adult patients with hormone ...